# Resource Summary Report

Generated by FDI Lab - SciCrunch.org on May 7, 2024

## Huh-7

RRID:CVCL_0336
Type: Cell Line

### Proper Citation

(RRID:CVCL_0336)

### Cell Line Information

**URL:** https://web.expasy.org/cellosaurus/CVCL_0336

**Proper Citation:** (RRID:CVCL_0336)

**Description:** Cell line Huh-7 is a Cancer cell line with a species of origin Homo sapiens (Human)

**Sex:** Male

**Defining Citation:** PMID:6203805, PMID:8224613, PMID:8389256, PMID:8835345, PMID:9290701, PMID:9359923, PMID:10523694, PMID:11152498, PMID:12029633, PMID:15708988, PMID:15767549, PMID:16935386, PMID:20215515, PMID:22460905, PMID:23285155, PMID:23505090, PMID:23887712, PMID:24973239, PMID:25485619, PMID:25574106, PMID:25877200, PMID:26589293, PMID:27329724, PMID:27397505, PMID:28196595, PMID:29610054, PMID:29774518, PMID:30894373, PMID:31063779, PMID:31068700, PMID:31378681, PMID:31395879, PMID:31903165, PMID:31978347, PMID:32899426, PMID:33193621, PMID:34320349, PMID:34800366, PMID:35839778

**Comments:** Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: SNP array analysis., Omics: Protein expression by reverse-phase protein arrays., Omics: Mitochondrial proteome analysis., Omics: miRNA expression profiling., Omics: Genome sequenced., Omics: DNA methylation analysis., Omics: Deep quantitative proteome analysis., Omics: Deep exome analysis., Population: Japanese., Part of: TCGA-110-CL cell line panel., Part of: MD Anderson Cell Lines Project., Part of: Liver Cancer Model Repository (LIMORE)., Part of: JFCR45 cancer cell line panel., Part of: ENCODE project common cell types; tier 3., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

**Category:** Cancer cell line

**Name:** Huh-7

**Synonyms:** HuH-7, HUH-7, HuH7, Huh7, HUH7, HUH7.0, JTC-39, Japanese Tissue Culture-39

**Cross References:** BTO:BTO:0001950, CLO:CLO_0009989, CLO:CLO_0050850, CLO:CLO_0050853, EFO:EFO_0005384, MCCL:MCC:0000232, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-MTAB-7847, BioGRID_ORCS_Cell_line:641, BioSample:SAMN03471912, BioSample:SAMN03472130, BioSample:SAMN10987834, cancercelllines:CVCL_0336, CCLV:CCLV-RIE 1079, CCRID:1101HUM-PUMC000679, CCRID:3101HUMSCSP526, CCRID:3101HUMTCHu182, CCRID:5301HUM-KCB09070YJ, CCTCC:GDC0134, Cell_Model_Passport:SIDM00585, CGH-DB:453-3, CGH-DB:9072-4, ChEMBL-Cells:CHEMBL3307515, ChEMBL-Targets:CHEMBL614039, CLS:300156, Cosmic:871515, Cosmic:873395, Cosmic:907071, Cosmic:945154, Cosmic:948063, Cosmic:979730, Cosmic:1187330, Cosmic:1351512, Cosmic:1518226, Cosmic:1622751, Cosmic:1995450, Cosmic:2023863, Cosmic:2162528, Cosmic:2321028, Cosmic:2668283, Cosmic:2674232, Cosmic:2771603, Cosmic:2773182, Cosmic-CLP:907071, DepMap:ACH-000480, EGA:EGAS00001000610, EGA:EGAS00001000978, ENCODE:ENCBS226AAA, FCS-free:213-2-437-1-3-3, FCS-free:213-2-540-1-3-3, GDSC:907071, GEO:GSM207048, GEO:GSM388882, GEO:GSM388883, GEO:GSM388884, GEO:GSM481447, GEO:GSM501781, GEO:GSM565880, GEO:GSM816641, GEO:GSM827171, GEO:GSM887149, GEO:GSM888221, GEO:GSM936763, GEO:GSM1178257, GEO:GSM1178258, GEO:GSM1374566, GEO:GSM1669919, GEO:GSM2551570, IARC_TP53:2011, JCRB:JCRB0403, KCB:KCB 200970YJ, KCLB:60104, LiGeA:CCLE_245, LIMORE:HuH7, LINCS_LDP:LCL-1926, Lonza:244, PharmacoDB:HuH7_640_2019, PRIDE:PXD001339, PRIDE:PXD005955, PRIDE:PXD008190, PRIDE:PXD023760, PRIDE:PXD028149, PRIDE:PXD028169, PRIDE:PXD028693, PRIDE:PXD030304, Progenetix:CVCL_0336, PubChem_Cell_line:CVCL_0336, RCB:RCB1366, RCB:RCB1942, TKG:TKG 0206, TOKU-E:3614, Ubigene:YC-D001, Wikidata:Q27555640

**ID:** CVCL_0336

## Ratings and Alerts

No rating or validation information has been found for Huh-7.

No alerts have been found for Huh-7.

## Data and Source Information

**Source:** Cellosaurus

## Usage and Citation Metrics

We found 9198 mentions in open access literature.

**Listed below are recent publications.** The full list is available at FDI Lab - SciCrunch.org.


Lachiondo-Ortega S, et al. (2024) SUMOylation controls Hu antigen R posttranscriptional activity in liver cancer. Cell reports, 43(3), 113924.

Jiang Z, et al. (2024) CREB3L4 promotes hepatocellular carcinoma progression and decreases sorafenib chemosensitivity by promoting RHEB-mTORC1 signaling pathway. iScience, 27(2), 108843.

Zhou HM, et al. (2024) Inhibition of RhoGEF/RhoA alleviates regorafenib resistance and cancer stemness via Hippo signaling pathway in hepatocellular carcinoma. Experimental cell research, 436(1), 113956.

Zhang L, et al. (2024) SARS-CoV-2 BA.2.86 enters lung cells and evades neutralizing antibodies with high efficiency. Cell, 187(3), 596.

Ogega CO, et al. (2024) Convergent evolution and targeting of diverse E2 epitopes by human broadly neutralizing antibodies are associated with HCV clearance. Immunity.

Kato H, et al. (2024) Histone methyltransferase SUV420H1/KMT5B contributes to poor prognosis in hepatocellular carcinoma. Cancer science, 115(2), 385.

Chan TS, et al. (2024) ASPM stabilizes the NOTCH intracellular domain 1 and promotes oncogenesis by blocking FBXW7 binding in hepatocellular carcinoma cells. Molecular oncology, 18(3), 562.

Shi Y, et al. (2024) A prognostic and immune related risk model based on zinc homeostasis in hepatocellular carcinoma. iScience, 27(4), 109389.

Deng R, et al. (2024) PZR suppresses innate immune response to RNA viral infection by inhibiting MAVS activation in interferon signaling mediated by RIG-I and MDA5. Antiviral research, 222, 105797.

Wang ZJ, et al. (2023) Upregulation of TUBG1 expression promotes hepatocellular carcinoma development. Medical oncology (Northwood, London, England), 40(3), 96.

Breitenecker K, et al. (2023) Synergism of the receptor tyrosine kinase Axl with ErbB receptors mediates resistance to regorafenib in hepatocellular carcinoma. Frontiers in oncology, 13, 1238883.

Chen DY, et al. (2023) Cell culture systems for isolation of SARS-CoV-2 clinical isolates and generation of recombinant virus. iScience, 26(5), 106634.

Weklak D, et al. (2023) Insights from the Construction of Adenovirus-Based Vaccine Candidates against SARS-CoV-2: Expecting the Unexpected. Viruses, 15(11).

Chen PD, et al. (2023) Decreased B4GALT1 promotes hepatocellular carcinoma cell invasiveness by regulating the laminin-integrin pathway. Oncogenesis, 12(1), 49.

Wang Z, et al. (2023) XPO1 intensifies sorafenib resistance by stabilizing acetylation of NPM1 and enhancing epithelial-mesenchymal transition in hepatocellular carcinoma. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 160, 114402.

Yang X, et al. (2023) PPM1H is down-regulated by ATF6 and dephosphorylates p-RPS6KB1 to inhibit progression of hepatocellular carcinoma. Molecular therapy. Nucleic acids, 33, 164.

Smith JR, et al. (2023) MEF2A suppresses stress responses that trigger DDX41-dependent IFN production. Cell reports, 42(8), 112805.

Kim SM, et al. (2023) SARS-CoV-2 variants with NSP12 P323L/G671S mutations display enhanced virus replication in ferret upper airways and higher transmissibility. Cell reports, 42(9), 113077.

Zhang J, et al. (2023) PSMD4 drives progression of hepatocellular carcinoma via Akt/COX2 pathway and p53 inhibition. Human cell, 36(5), 1755.

Zhang B, et al. (2023) An HBV susceptibility variant of KNG1 modulates the therapeutic effects of interferons ? and ?1 in HBV infection by promoting MAVS lysosomal degradation. EBioMedicine, 94, 104694.